HOME >> MEDICINE >> NEWS
Novel stem cell trial in heart failure patients to begin

PITTSBURGH, May 12 The University of Pittsburgh Medical Center (UPMC) is beginning a clinical trial to evaluate the safety and feasibility of a potential treatment for congestive heart failure that involves injecting a patient's own bone marrow-derived stem cells directly into the heart muscle. The procedure is expected to be performed in five to 10 patients who are scheduled to receive a heart assist device as a bridge to organ transplantation.

The stem cell trial is one of only a handful that has been cleared by the U.S. Food and Drug Administration (FDA) for heart disease. And because most patients in the UPMC study will eventually receive transplants, the trial represents the first time researchers will be able to examine a human heart treated with stem cells, an opportunity that should help solve some of the mystery as well as resolve scientific debate about just how it is that stem cells work to improve heart function.

Despite advances that have given rise to more effective medical and surgical therapies, including the use of heart assist devices, heart disease continues to exact an economic burden and be a major cause of death in the United States. As such, researchers have looked to the potential of stem cells as a treatment for congestive heart failure and other heart disease. Laboratory studies indicating that a subset of stem cells from bone marrow can generate new heart cells and blood vessels have spawned interest in performing clinical studies. While relatively few such studies have been conducted, and most have been done abroad, preliminary results have shown that blood flow and heart function improve in patients receiving the stem cell therapy.

However, to date, there has been no research in humans that helps explain why such improvements are seen, raising questions that have become the crux of scientific debate about the mechanism and action of these cells once introduced into the heart.

"People have questioned wheth
'"/>


12-May-2005


Page: 1 2 3

Related medicine news :

1. Novel candidate biomarker for heart failure also strongly predicts risk of death
2. Novel treatments may help alleviate constipation, IBS in women
3. Novel catheter technique successfully patches holes in the heart
4. Novel anti-oxidant and anti-inflammatory agent shows effectiveness on key endpoints in trial
5. Novel Ames Lab composite may replace depleted uranium
6. Novel computed imaging technique uses blurry images to enhance view
7. Novel brain areas associated with the recognition of gender, ethnicity and the identity of faces
8. Novel program enhances dementia caregivers quality of life
9. Novel gene therapy may lead to cure in hemophilia A patients
10. Novel therapy combinations gain ground in treating hepatitis
11. Novel stem cell technology leads to better spinal cord repair

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Novel stem cell trial heart failure patients begin

(Date:6/19/2013)... 2013 In honor of women everywhere, ... providing information that women can use to improve their ... women should pay close attention to their health, as ... changes a woman’s body undergoes while pregnant can increase ... says Dr. Ray Workman, a leading vein doctor at ...
(Date:6/19/2013)... Washington, DC (PRWEB) June 19, 2013 ... experiment in the history of managed care. As ... find coverage through the new state-based and federally ... requirements for essential health benefits, and examples of ... some states, industry-leading health business information publisher Atlantic ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Scott Tischler of ... curb this swim suit season. , 1.    The very first thing ... big tall glass of ice cold water. The body is ... water. This will keep the body hydrated and will also ... body has to raise the temperature of the water to ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 As Mirena ... LLP highlights a recent news story from an NBC ... effects of the hormone-based contraceptive device. The Rottenstein Law ... to file Mirena lawsuits and who are ... The U.S. Food and Drug Administration has logged more ...
(Date:6/19/2013)... Transvaginal mesh lawsuits are moving along in the New ... how to handle evidence in the C.R. Bard lawsuits, specifically ... components removed from patients. The Rottenstein Law Group LLP maintains ... about the device and a guide on how to file ... the medical facilities that currently hold them and are to ...
Breaking Medicine News(10 mins):Health News:Novant Health Vein Specialists Promotes Women’s Health with Social Media Campaign 2Health News:New Special Report Provides Comprehensive Overview of New Health Insurance Exchange Marketplaces 2Health News:Rottenstein Law Group LLP Comments on News Reports of Mirena IUD Side Effects 2Health News:Transvaginal Mesh Lawsuit News: NJ Mesh Consolidation Cases Moving Along, Rottenstein Law Group LLP Reports 2
(Date:6/18/2013)... , June 18, 2013  Isis Pharmaceuticals, Inc. (NASDAQ: ... that management will present a general corporate update in conjunction ... on Tuesday, June 25 at 2:10 p.m. Pacific Time in ... for the meeting is as follows: 2:00 p.m. – 2:10 ... as of April 26, 2013) 2:10 p.m. – 3:15 p.m. ...
(Date:6/17/2013)... WASHINGTON , June 17, 2013 ... ) presented additional data today at ENDO 2013, ... demonstrating that tasimelteon can entrain (synchronize) both melatonin ... potential to reset the master body clock and ... Non-24-Hour Disorder (Non-24).  The SET (Safety and Efficacy ...
(Date:6/17/2013)... June 17, 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... it has filed a preliminary prospectus supplement to its effective ... a similar filing with securities regulatory authorities in each of ... with a public offering of its common shares to raise ... The Company will also grant to the underwriters of the ...
Breaking Medicine Technology:Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4Valeant Pharmaceuticals Announces Public Offering Of Common Shares 2Valeant Pharmaceuticals Announces Public Offering Of Common Shares 3Valeant Pharmaceuticals Announces Public Offering Of Common Shares 4
Cached News: